Findings

What do systematic reviews say?

43 questions · 43 findings · 16 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 11 · 25.6%GRADE not reported 7 · 16.3%Very low 7 · 16.3%Low 11 · 25.6%Moderate 6 · 14%High 1 · 2.3%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Morning vs evening inhalation of dornase alfa · FVC (% predicted) change from baseline
  Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  25 participants
  Low
Direct match · question page
- Morning vs evening inhalation of dornase alfa · FEV1 (% predicted) change from baseline
  Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  25 participants
  Low
Direct match · question page
- Morning vs evening inhalation of dornase alfa · FEF25-75 (% predicted)
  Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Direct match · question page
- Morning vs evening inhalation of dornase alfa · Measures of QoL and symptom scores
  Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  25 participants
  Low
Direct match · question page
- Morning vs evening inhalation of dornase alfa · Adverse effects
  Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  25 participants
  Low

Morning vs evening inhalation of dornase alfa

Adverse effects · adults and children with cystic fibrosis

1 finding from 1 review

Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
25 participants
Low

Morning vs evening inhalation of dornase alfa

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

Morning showed no clear difference in FEV1 (% predicted) change from baseline compared with evening inhalation of dornase alfa (low certainty).

1 finding from 1 review

Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
25 participants
Low

Morning vs evening inhalation of dornase alfa

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

Morning showed no clear difference in FVC (% predicted) change from baseline compared with evening inhalation of dornase alfa (low certainty).

1 finding from 1 review

Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
25 participants
Low

Morning vs evening inhalation of dornase alfa

Measures of QoL and symptom scores · adults and children with cystic fibrosis

1 finding from 1 review

Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
25 participants
Low

Morning vs evening inhalation of dornase alfa

FEF25-75 · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Morning bright light vs afternoon bright light

Alertness · daytime workers

Morning bright light showed no clear difference in alertness compared with afternoon bright light (low certainty).

1 finding from 1 review

Workplace lighting for improving alertness and mood in daytime workers 2018 · Cochrane Headline outcomes only
MD 7
1 study · 30 participants
Low

Morning bright light vs afternoon bright light

Mood · daytime workers

Morning bright light showed no clear difference in mood compared with afternoon bright light (low certainty).

1 finding from 1 review

Workplace lighting for improving alertness and mood in daytime workers 2018 · Cochrane Headline outcomes only
RR 1.6 [0.81, 3.2]
1 study · 30 participants
Low

Morning bright light vs afternoon bright light

Frequency of adverse events ( · daytime workers

Morning bright light showed no clear difference in adverse events (frequency) compared with afternoon bright light (low certainty).

1 finding from 1 review

Workplace lighting for improving alertness and mood in daytime workers 2018 · Cochrane Headline outcomes only
RR 0.53 [0.26, 1.07]
1 study · 30 participants
Low

Radiotherapy (morning) vs Afternoon radiotherapy

Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…

Morning radiotherapy showed no clear difference in total mortality compared with afternoon radiotherapy; GRADE not reported.

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy 2010 · Cochrane All outcomes
2 years
RR 1.09 [0.74, 1.59]
1 study · 216 participants
GRADE not reported

Radiotherapy (morning) vs Afternoon radiotherapy

Quality of life · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy 2010 · Cochrane All outcomes
Bjarnason 2009: no statistically significant difference in quality of life scores (data not reported). Morning radiotherapy was associated with significantly less weight loss after 5 months.
1 study · 216 participants
GRADE not reported

Radiotherapy (morning) vs Afternoon radiotherapy

Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…

Morning radiotherapy showed no clear difference in locoregional control compared with afternoon radiotherapy; GRADE not reported.

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy 2010 · Cochrane All outcomes
HR 0.92 [0.60, 1.42]
1 study · 216 participants
GRADE not reported

Radiotherapy (morning) vs Radiotherapy (afternoon/evening)

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Radiotherapy (morning) showed no clear difference in oral mucositis (moderate to severe) compared with radiotherapy (afternoon/evening); GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.7 [0.48, 1.01]
1 study · 177 participants
GRADE not reported

Radiotherapy (morning) vs Radiotherapy (afternoon/evening)

Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
no estimate extracted
2 studies
GRADE not reported

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

QoL · people with CAH

The review found no eligible studies for this question.

1 finding from 1 review

Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

Androgen normalisation · people with CAH

1 finding from 1 review

Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
15 participants
Very low

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

Prevention of adrenal crisis · people with CAH

The review found no eligible studies for this question.

1 finding from 1 review

Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

Presence of osteopenia · people with CAH

The review found no eligible studies for this question.

1 finding from 1 review

Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

Presence of testicular or ovarian adrenal rest tumours · people with CAH

The review found no eligible studies for this question.

1 finding from 1 review

Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

Subfertility · people with CAH

The review found no eligible studies for this question.

1 finding from 1 review

Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

Final adult height · people with CAH

The review found no eligible studies for this question.

1 finding from 1 review

Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found